173 related articles for article (PubMed ID: 2088770)
1. Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects.
Barzaghi N; Crema F; Gatti G; Pifferi G; Perucca E
Eur J Drug Metab Pharmacokinet; 1990; 15(4):333-8. PubMed ID: 2088770
[TBL] [Abstract][Full Text] [Related]
2. Comparative bioavailability of Silipide, a new flavanolignan complex, in rats.
Morazzoni P; Magistretti MJ; Giachetti C; Zanolo G
Eur J Drug Metab Pharmacokinet; 1992; 17(1):39-44. PubMed ID: 1499596
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics of silipide and silymarin in rats.
Morazzoni P; Montalbetti A; Malandrino S; Pifferi G
Eur J Drug Metab Pharmacokinet; 1993; 18(3):289-97. PubMed ID: 8149949
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients.
Schandalik R; Gatti G; Perucca E
Arzneimittelforschung; 1992 Jul; 42(7):964-8. PubMed ID: 1329780
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers.
Gatti G; Perucca E
Int J Clin Pharmacol Ther; 1994 Nov; 32(11):614-7. PubMed ID: 7874377
[TBL] [Abstract][Full Text] [Related]
6. Bioavailability of a silybin-phosphatidylcholine complex in dogs.
Filburn CR; Kettenacker R; Griffin DW
J Vet Pharmacol Ther; 2007 Apr; 30(2):132-8. PubMed ID: 17348898
[TBL] [Abstract][Full Text] [Related]
7. Development of a HPLC-UV assay for silybin-phosphatidylcholine complex (silybinin capsules) and its pharmacokinetic study in healthy male Chinese volunteers.
Li W; Gao J; Zhao HZ; Liu CX
Eur J Drug Metab Pharmacokinet; 2006; 31(4):265-70. PubMed ID: 17315537
[TBL] [Abstract][Full Text] [Related]
8. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer.
Gallo D; Giacomelli S; Ferlini C; Raspaglio G; Apollonio P; Prislei S; Riva A; Morazzoni P; Bombardelli E; Scambia G
Eur J Cancer; 2003 Nov; 39(16):2403-10. PubMed ID: 14556934
[TBL] [Abstract][Full Text] [Related]
9. Superior silybin bioavailability of silybin-phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers.
Méndez-Sánchez N; Dibildox-Martinez M; Sosa-Noguera J; Sánchez-Medal R; Flores-Murrieta FJ
BMC Pharmacol Toxicol; 2019 Jan; 20(1):5. PubMed ID: 30635055
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction.
Schandalik R; Perucca E
Drugs Exp Clin Res; 1994; 20(1):37-42. PubMed ID: 7924893
[TBL] [Abstract][Full Text] [Related]
11. [Preparation of silybin-phospholipid complex and its bioavailability in rats].
Xiao YY; Song YM; Chen ZP; Ping QN
Yao Xue Xue Bao; 2005 Jul; 40(7):611-7. PubMed ID: 16196266
[TBL] [Abstract][Full Text] [Related]
12. Studies on the antioxidant and free radical scavenging properties of IdB 1016 a new flavanolignan complex.
Comoglio A; Leonarduzzi G; Carini R; Busolin D; Basaga H; Albano E; Tomasi A; Poli G; Morazzoni P; Magistretti MJ
Free Radic Res Commun; 1990; 11(1-3):109-15. PubMed ID: 2074043
[TBL] [Abstract][Full Text] [Related]
13. Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.
Li WY; Yu G; Hogan RM; Mohandas R; Frye RF; Gumpricht E; Markowitz JS
Clin Ther; 2018 Jan; 40(1):103-113.e1. PubMed ID: 29273470
[TBL] [Abstract][Full Text] [Related]
14. A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer.
Lazzeroni M; Guerrieri-Gonzaga A; Gandini S; Johansson H; Serrano D; Cazzaniga M; Aristarco V; Puccio A; Mora S; Caldarella P; Pagani G; Pruneri G; Riva A; Petrangolini G; Morazzoni P; DeCensi A; Bonanni B
Cancer Prev Res (Phila); 2016 Jan; 9(1):89-95. PubMed ID: 26526990
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.
Wen Z; Dumas TE; Schrieber SJ; Hawke RL; Fried MW; Smith PC
Drug Metab Dispos; 2008 Jan; 36(1):65-72. PubMed ID: 17913795
[TBL] [Abstract][Full Text] [Related]
16. Comparative bioavailability of silibinin in healthy male volunteers.
Kim YC; Kim EJ; Lee ED; Kim JH; Jang SW; Kim YG; Kwon JW; Kim WB; Lee MG
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):593-6. PubMed ID: 14692709
[TBL] [Abstract][Full Text] [Related]
17. The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats.
Yanyu X; Yunmei S; Zhipeng C; Qineng P
Int J Pharm; 2006 Jan; 307(1):77-82. PubMed ID: 16300915
[TBL] [Abstract][Full Text] [Related]
18. Lipid peroxidation and irreversible damage in the rat hepatocyte model. Protection by the silybin-phospholipid complex IdB 1016.
Carini R; Comoglio A; Albano E; Poli G
Biochem Pharmacol; 1992 May; 43(10):2111-5. PubMed ID: 1599497
[TBL] [Abstract][Full Text] [Related]
19. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells.
Kumar N; Rai A; Reddy ND; Raj PV; Jain P; Deshpande P; Mathew G; Kutty NG; Udupa N; Rao CM
Pharmacol Rep; 2014 Oct; 66(5):788-98. PubMed ID: 25149982
[TBL] [Abstract][Full Text] [Related]
20. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
Schrieber SJ; Hawke RL; Wen Z; Smith PC; Reddy KR; Wahed AS; Belle SH; Afdhal NH; Navarro VJ; Meyers CM; Doo E; Fried MW
Drug Metab Dispos; 2011 Dec; 39(12):2182-90. PubMed ID: 21865319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
